Skip to main content
main-content

Medicine Matters diabetes

Featured clinical trials

09-18-2017 | PCSK9 inhibitors | EASD 2017 | News

FOURIER: Evolocumab cardiovascular benefits extend to diabetes patients

A prespecified analysis of the FOURIER trial shows that the PCSK9 inhibitor evolocumab is as beneficial in patients with diabetes as in those without.

09-18-2017 | Glycemic control | EASD 2017 | News

J-DOIT3 supports intensive management to prevent diabetic complications

The J-DIOT3 trial results support the findings from Steno-2, showing that intensive risk factor management can reduce the risk for complications in patients with type 2 diabetes.

09-15-2017 | Hypoglycemia | EASD 2017 | News

Glycemic variability, hypoglycemia linked to poor outcomes in type 2 diabetes patients

Two secondary analyses of the DEVOTE trial suggest that type 2 diabetes patients with high day-to-day fasting glycemic variability and those who experience severe hypoglycemia are at increased risk for adverse outcomes.

09-15-2017 | Continuous glucose monitoring | EASD 2017 | News

CGM use during pregnancy improves maternal glycemic control, neonatal outcomes

The CONCEPTT trial results suggest that the use of continuous glucose monitoring by pregnant women with type 1 diabetes improves glycemic control and neonatal outcomes relative to standard glucose monitoring.

09-15-2017 | Exenatide | EASD 2017 | News

EXSCEL: Near miss for exenatide cardioprotection

The results of the Exenatide Study of Cardiovascular Event Lowering study show that the glucagon-like peptide-1 receptor agonist has a neutral cardiovascular effect, the investigators have reported at the EASD annual meeting, in Lisbon, Portugal.

09-14-2017 | Dapagliflozin | EASD 2017 | News

DEPICT-1 findings support dapagliflozin as add-on therapy for type 1 diabetes

Dapagliflozin is a promising adjunct treatment to insulin for patients with type 1 diabetes, suggest phase III trial results presented at the EASD annual meeting in Lisbon, Portugal, and published simultaneously in The Lancet Diabetes & Endocrinology.

09-14-2017 | Sotagliflozin | EASD 2017 | News

Add-on sotagliflozin improves glycemic control in type 1 diabetes patients

Results of the inTandem3 study suggest that adding the sodium–glucose cotransporter 1 and 2 inhibitor sotagliflozin to insulin treatment improves glycemic control among patients with type 1 diabetes, but at the cost of an increased risk for ketoacidosis.

09-13-2017 | Acarbose | EASD 2017 | News

ACE results suggest no reduction in CV risk with acarbose treatment

The α-glucosidase inhibitor acarbose does not reduce cardiovascular risk but could decrease the risk for developing type 2 diabetes among patients with coronary heart disease and impaired glucose tolerance, results of the phase IV placebo-controlled ACE trial suggest.

09-13-2017 | Pioglitazone | EASD 2017 | News

TOSCA.IT: Similar long-term CV safety profile for pioglitazone, sulfonylurea

 The TOCSA.IT investigators have found no differences in cardiovascular disease outcomes between patients with type 2 diabetes taking pioglitazone versus sulfonylurea over nearly 5 years.

Expert commentaries

09-20-2017 | EASD 2017 | Video

Expert commentary: The CONCEPTT trial

Harold de Valk discusses the importance of the ​​​​​​​CONCEPTT trial results for pregnant women with type 1 diabetes.
Read the accompanying news story

09-20-2017 | EASD 2017 | Video

Expert commentary: DEPICT-1 and inTandem3

Parth ​​​​​​​Narendran discusses the findings of two trials testing SGLT2 inhibitors in patients with type 1 diabetes.
Read the accompanying news stories on the DEPICT-1 and inTandem3 results

09-19-2017 | EASD 2017 | Video

Expert commentary: The TOSCA.IT trial

Marja-Riitta Taskinen gives her view of the TOSCA.IT trial.
Read the accompanying news story

09-18-2017 | EASD 2017 | Video

Expert commentary: The ACE trial

Editorial board member Carol Wysham gives her view of the ACE trial.
Read the accompanying news story

Research news: Diabetes medications

09-22-2017 | Insulin glargine | EASD 2017 | News

Higher dose of insulin glargine supported for type 2 diabetes

Results of a pooled analysis suggest that the 300 U/mL dose of insulin glargine is associated with a lower risk for hypoglycemia than the 100 U/mL dose.

09-21-2017 | Type 2 diabetes | EASD 2017 | News

Novel compounds show promise for type 2 diabetes

Study results presented at the EASD annual meeting in Lisbon, Portugal, demonstrated the potential of several novel therapies for the treatment of obesity-related metabolic dysfunction and type 2 diabetes.

09-20-2017 | Hypoglycemia | EASD 2017 | News

Hypoglycemia: Risk factors and Ramadan

Results presented during an EASD annual meeting session on hypoglycemia covered risk factors and consequences, and looked at the optimal insulin management approach for diabetes patients wishing to observe Ramadan.

09-20-2017 | Non-alcoholic fatty liver disease | EASD 2017 | News

NAFLD: The associated risks and potential treatments

Researchers presented the results of several studies investigating the risks associated with nonalcoholic fatty liver disease and potential treatment strategies at the EASD annual meeting in Lisbon, Portugal.

09-19-2017 | Sotagliflozin | EASD 2017 | News

Sotagliflozin as adjunct therapy to insulin ‘might be a treatment option’ for type 1 diabetes

Sotagliflozin may be an effective add-on therapy to insulin for patients with type 1 diabetes, but the benefits are less clear in a young adult population, suggest the results of two studies presented at the EASD annual meeting in Lisbon, Portugal.

09-19-2017 | Empagliflozin | EASD 2017 | News

Benefits of empagliflozin unlikely to be mediated by control of cardiovascular risk factors

Analysis of data from the EMPA-REG OUTCOME trial suggests that the beneficial effects of empagliflozin on mortality risk in patients with type 2 diabetes and established cardiovascular disease occur independently of its influence on traditional cardiovascular risk factors.

09-18-2017 | PCSK9 inhibitors | EASD 2017 | News

FOURIER: Evolocumab cardiovascular benefits extend to diabetes patients

A prespecified analysis of the FOURIER trial shows that the PCSK9 inhibitor evolocumab is as beneficial in patients with diabetes as in those without.

09-15-2017 | Hypoglycemia | EASD 2017 | News

Glycemic variability, hypoglycemia linked to poor outcomes in type 2 diabetes patients

Two secondary analyses of the DEVOTE trial suggest that type 2 diabetes patients with high day-to-day fasting glycemic variability and those who experience severe hypoglycemia are at increased risk for adverse outcomes.

09-15-2017 | Exenatide | EASD 2017 | News

EXSCEL: Near miss for exenatide cardioprotection

The results of the Exenatide Study of Cardiovascular Event Lowering study show that the glucagon-like peptide-1 receptor agonist has a neutral cardiovascular effect, the investigators have reported at the EASD annual meeting, in Lisbon, Portugal.

09-14-2017 | PCSK9 inhibitors | EASD 2017 | News

Alirocumab dyslipidemia benefits extended to type 1 patients

The effect of the PCSK9 inhibitor alirocumab on dyslipidemia in patients with type 1 diabetes is consistent with that seen in the type 2 population, the ODYSSEY team has revealed.

Research news: Diabetic complications

09-22-2017 | Insulin glargine | EASD 2017 | News

Higher dose of insulin glargine supported for type 2 diabetes

Results of a pooled analysis suggest that the 300 U/mL dose of insulin glargine is associated with a lower risk for hypoglycemia than the 100 U/mL dose.

09-22-2017 | Medication adherence | EASD 2017 | News

Sliding scale for medication adherence and CVD protection

Adherence to lipid-lowering drugs is crucial for reducing cardiovascular disease risk among patients with type 2 diabetes, but taking only some of the prescribed medication is better than none at all, study results suggest.

09-20-2017 | Hypoglycemia | EASD 2017 | News

Hypoglycemia: Risk factors and Ramadan

Results presented during an EASD annual meeting session on hypoglycemia covered risk factors and consequences, and looked at the optimal insulin management approach for diabetes patients wishing to observe Ramadan.

09-20-2017 | Non-alcoholic fatty liver disease | EASD 2017 | News

NAFLD: The associated risks and potential treatments

Researchers presented the results of several studies investigating the risks associated with nonalcoholic fatty liver disease and potential treatment strategies at the EASD annual meeting in Lisbon, Portugal.

09-19-2017 | Sotagliflozin | EASD 2017 | News

Sotagliflozin as adjunct therapy to insulin ‘might be a treatment option’ for type 1 diabetes

Sotagliflozin may be an effective add-on therapy to insulin for patients with type 1 diabetes, but the benefits are less clear in a young adult population, suggest the results of two studies presented at the EASD annual meeting in Lisbon, Portugal.

09-19-2017 | Cardiovascular outcomes | EASD 2017 | News

Simple wellbeing query predicts MACE in type 2 diabetes

Asking two simple questions about the vitality and energy of patients with type 2 diabetes may help healthcare providers to predict their risk for major adverse cardiovascular events.

09-18-2017 | Glycemic control | EASD 2017 | News

J-DOIT3 supports intensive management to prevent diabetic complications

The J-DIOT3 trial results support the findings from Steno-2, showing that intensive risk factor management can reduce the risk for complications in patients with type 2 diabetes.

09-15-2017 | Hypoglycemia | EASD 2017 | News

Glycemic variability, hypoglycemia linked to poor outcomes in type 2 diabetes patients

Two secondary analyses of the DEVOTE trial suggest that type 2 diabetes patients with high day-to-day fasting glycemic variability and those who experience severe hypoglycemia are at increased risk for adverse outcomes.

09-15-2017 | Physical activity | EASD 2017 | News

Exercise important for type 1 diabetes patients regardless of CKD

Physical activity is linked to lower mortality risk among patients with type 1 diabetes irrespective of whether they have comorbid chronic kidney disease, study results suggest.

09-14-2017 | Dapagliflozin | EASD 2017 | News

DEPICT-1 findings support dapagliflozin as add-on therapy for type 1 diabetes

Dapagliflozin is a promising adjunct treatment to insulin for patients with type 1 diabetes, suggest phase III trial results presented at the EASD annual meeting in Lisbon, Portugal, and published simultaneously in The Lancet Diabetes & Endocrinology.

Other research news

09-22-2017 | Older adults | EASD 2017 | News

Optimizing outcomes: System and patient factors

An EASD session on optimizing patient outcomes included research into the effect of guideline adherence, predictors of changes in medication adherence, and overtreatment of older people with diabetes.

09-19-2017 | Genetics | EASD 2017 | News

Genetics point way to type 1 and monogenic diagnosis and prediction

Studies presented in a session on the genetics of diabetes, at the EASD annual meeting in Lisbon, Portugal, demonstrated the heterogeneity of type 1 diabetes risk and the predictive and diagnostic power of a genetic risk score.

image credits